Gallitto Enrico, Gargiulo Mauro, Freyrie Antonio, Pini Rodolfo, Mascoli Chiara, Ancetti Stefano, Faggioli Gianluca, Stella Andrea
Vascular Surgery, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
Vascular Surgery, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
J Vasc Surg. 2017 Sep;66(3):696-704.e5. doi: 10.1016/j.jvs.2016.12.129. Epub 2017 Mar 31.
The aim of this paper was to report early and midterm results of endovascular repair of urgent thoracoabdominal aortic aneurysms (TAAAs) by the off-the-shelf multibranched Zenith t-Branch endograft (Cook Medical, Bloomington, Ind).
Between January 2014 and April 2016, all patients with urgent TAAAs (asymptomatic with diameter >8 cm, symptomatic, or ruptured TAAAs) and aortoiliac anatomic feasibility underwent endovascular repair by t-Branch and were prospectively enrolled. Clinical, morphologic, intraoperative, and postoperative data were recorded. Follow-up was performed by duplex ultrasound, contrast-enhanced duplex ultrasound, and computed tomography angiography. Early end points were technical success (absence of type I or type III endoleak, loss of target visceral vessels [TVVs], conversion to open repair, or 24-hour mortality), spinal cord ischemia, and 30-day mortality. Follow-up end points were survival, TVV patency, type I or type III endoleaks, and freedom from reintervention.
Seventeen patients (male, 71%; age, 73 ± 6 years; American Society of Anesthesiologists class 3/4, 60%/40%) affected by type II (47%), III (29%), and IV (24%) TAAAs were enrolled. The indications for t-Branch were as follows: contained TAAA rupture, four (24%); symptomatic TAAA (pain or peripheral embolism), four (24%); and TAAA diameter ≥8 cm, nine (52%). The mean TAAA diameter was 80 ± 19 mm, with 63 TVVs. Fifteen patients (87%) needed adjunctive intraoperative procedures: 14 proximal thoracic endografts (thoracic endovascular aortic repair), 1 left carotid-subclavian bypass, 2 endovascular hypogastric branches, and 2 surgical iliac conduits. In four cases (24%), a significant malorientation (≥60 degrees) of the main body occurred during t-Branch deployment. Technical success was achieved in 14 cases (82%), with technical failures consisting of the loss of three renal arteries (TVV patency, 95%). Spinal cord ischemia occurred in one case (6%) with temporary paraparesis. The 30-day mortality was 6% (one patient with ruptured type II TAAA died on postoperative day 7 of respiratory failure). Renal function worsening occurred in four patients (25%), with one case requiring permanent hemodialysis. The mean follow-up was 11 ± 9 months. Survival at 1 month, 6 months, and 12 months was 94%, 82%, 82%, respectively. No TAAA-related mortality and TVV occlusion occurred in the follow-up. One type III endoleak was detected at 3 months and successfully treated. Freedom from reintervention at 1 month, 6 months, and 12 months was 88%, 82%, and 82%, respectively.
The off-the-shelf multibranched endograft is a safe and effective therapeutic option for urgent total endovascular TAAA repair for which a custom-made endograft is not obtainable in due time. However, the complex anatomy of these aneurysms needs a number of adjunctive and complex intraoperative procedures to achieve a durable repair.
本文旨在报告使用现成的多分支Zenith t型分支血管内移植物(库克医疗公司,印第安纳州布卢明顿)对急诊胸腹主动脉瘤(TAAA)进行血管内修复的早期和中期结果。
2014年1月至2016年4月期间,所有患有急诊TAAA(直径>8 cm无症状、有症状或破裂的TAAA)且腹主动脉-髂动脉解剖结构可行的患者均接受了t型分支血管内修复,并进行前瞻性入组。记录临床、形态学、术中及术后数据。通过双功超声、增强双功超声和计算机断层血管造影进行随访。早期终点包括技术成功(无I型或III型内漏、目标内脏血管[TVV]丢失、转为开放修复或24小时死亡率)、脊髓缺血和30天死亡率。随访终点包括生存率、TVV通畅率、I型或III型内漏以及无需再次干预。
纳入了17例患者(男性,71%;年龄,73±6岁;美国麻醉医师协会分级3/4级,60%/40%),其中II型(47%)、III型(29%)和IV型(24%)TAAA患者。t型分支血管内移植物的适应证如下:局限性TAAA破裂,4例(24%);有症状的TAAA(疼痛或周围栓塞),4例(24%);TAAA直径≥8 cm,9例(52%)。TAAA平均直径为80±19 mm,有63条TVV。15例患者(87%)需要术中辅助操作:14例近端胸段血管内移植物(胸段血管内主动脉修复)、1例左颈总动脉-锁骨下动脉旁路移植术、2例血管内髂内分支和2例手术髂动脉导管。4例(24%)患者在t型分支血管内移植物置入过程中主体出现明显的方向错误(≥60度)。14例(82%)患者获得技术成功,技术失败包括3条肾动脉丢失(TVV通畅率,95%)。1例(6%)患者发生脊髓缺血并出现短暂性截瘫。30天死亡率为6%(1例II型破裂TAAA患者术后第7天死于呼吸衰竭)。4例患者(25%)肾功能恶化,1例需要长期血液透析。平均随访时间为11±9个月。1个月、6个月和12个月时的生存率分别为94%、82%、82%。随访期间未发生与TAAA相关的死亡和TVV闭塞。3个月时检测到1例III型内漏并成功治疗。1个月、6个月和12个月时无需再次干预的比例分别为88%、82%和82%。
对于无法及时获得定制血管内移植物的急诊全血管内TAAA修复,现成的多分支血管内移植物是一种安全有效的治疗选择。然而,这些动脉瘤复杂的解剖结构需要一些辅助和复杂的术中操作才能实现持久修复。